Direct Binding of Complement Component C1q to Human Immunodeficiency Virus (HIV) and Human T Lymphotrophic Virus-I (HTLV-I) Coinfected Cells

AIDS Research and Human Retroviruses

Volumn 7, Issue 7, 1991, Pages 579-585

  Spear, Gregory T ^a   Jiang, Haixiang ^a   Sullivan, Brenda L ^a   Gewürz, Henry ^a   Landay, Alan L ^a   Lint, Thomas F ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C1Q;

ARTICLE; COMPLEMENT ACTIVATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS 1; NONHUMAN; SUPERINFECTION; VIRUS ACTIVATION;

CELL LINE; COMPLEMENT 1Q; COMPLEMENT ACTIVATION; HIV-1; HUMAN; HUMAN T-LYMPHOTROPIC VIRUS 1; SUPPORT, U.S. GOV'T, P.H.S.; VIRUS REPLICATION;

EID: 0025880239     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.1991.7.579     Document Type: Article

References (28)

1. Hirsch RL: The complement system: Its importance in the host response to viral infection. Microbiol Rev 1982;46:71–85.
2. Welsh RM, Cooper NR, Jensen FC, and Oldstone MBA: Human serum lyses RNA tumour viruses. Nature 1975;257:612–614.
3. Cooper NR, Jensen FC, Welsh, and Oldstone MBA. Lysis of RNA tumor viruses by human serum: Direct antibody-independent triggering of the classical complement pathway. J Exp Med 1976;144:970–984.
4. Banapour B, Sernatinger J, and Levy JA. The AIDS-associated retrovirus is not sensitive to lysis or inactivation by human serum. Virology 1986;152:268–271.
5. Hoshino H, Tanaka H, Miwa M, and Okada H. Human T-cell leukemia virus is not lysedby human serum. Nature 1984:310:324–325.
6. Sölder BM, Schulz TF, Hengster P, Löwer J, Larcher C, Bitterlich G, Kurth R, Wachter H, and Dierich MP. HIV and HIV-infected cells differentially activate the human complement system independent of antibody. Immunol Let 1989;22:135–146.
7. Spear GT, Landay AL, Sullivan BL, Dittel B, and Lint TF: Activation of complement on the surface of cells infected by human immunodeficiency virus. J Immunol 1990;144:1490–1496.
8. Bartholomew C, Blattner W, and Cleghorn F: Progression to AIDS in homosexual men co-infected with HIV and HTLV-I in Trinidad. Lancet 1987:2:1469.
9. Shibata D, Brynes RK, Rabinowitz A, Hanson CA, Slovak ML, Spira TJ, and Gill P: Human T-cell lymphotropic virus type I (HTLV-I)-associated adult T-cell leukemia-lymphoma in a patient infected with human immunodeficiency virus type 1 (HIV-1). Ann Int Med 1989;111:871–875.
10. Page JB, Lai S, Chitwood DD, Klimas NG, Smith PC, and Fletcher MA. HTLV-I/II seropositivity and death from AIDS among HIV-1 seropositive intravenous drug users. Lancet 1990:335:1439–1441.
11. Gazdar AF, Carney DN, Bunn PA, Russell EK, Jaffe ES, Schechter GP, and Guccion JG: Mitogen requirements for the in vitro propagation of cutaneous T-cell lymphomas. Blood 1980;55:409–417.
12. Popovic M, Sarngadharan MG, Read E, and Gallo RC: Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 1984;223:497–499.
13. Harada S, Kowanagi Y, and Yamamoto N: Infection of HTLV-III/LAV in HTLV-I carrying cells MT-2 and MT-4 and application in a plaque assay. Science 1985;229:563–565.
14. Slamon DJ, Tohno KS, Cline MJ, Golde DW, and Chen ISY: Identification of the putative transforming protein of the human T-cell leukemia viruses HTLV-I and HTLV-II. Science 1984;226:61–65.
15. Koeffler HP, Chen ISY, and Golde DW: Characterization of a novel HTLV-infected cell line. Blood 1984;64:482–490.
16. Tenner AJ, Lesavre PH, and Cooper NR: Purification and radiolabeling of human C1q. J Immunol 1981;127:648–653.
17. Reid KBM, Sim RB, and Faiers AP: Inhibition of the reconstitution of the haemolytic activity of the first component of human complement by a pepsin-derived fragment of subcomponent Clq. Biochem J 1977;161:239–248.
18. Paques EP, Huber R, and Priess H: Isolation of the globular region of the subcomponent q of the Cl component of complement. Hoppe-Seyler's Z Physiol Chem 1979;360:177–189.
19. Hughes-Jones NC, and Gardner B: Reaction between the isolated globular sub-units of the complement component Clq and IgG-complexes. Mol Immunol 1979;16:697–710.
20. Reid KBM: Isolation, by partial pepsin digestion, of the three collagen-like regions present in subcomponent Clq of the first component of human complement. Biochem J 1976;155:5–9.
21. Siegel RC, and Schumaker VN: Measurement of the association constants of the complexes formed between intact Clq or pepsin-treated Clq stalks and the unactivated or activated Clr2Cls2 tetramers. Mol Immunol 1983;20:53–61.
22. Lachmann PJ, and Hobart MJ: In: Handbook of Experimental Immunology. Vol. 1, Immunochemistry. DM Weir (ed.), Oxford: Blackwell Scientific Publications, 1978; pp 5A. 1–5A. 16.
23. Reid KBM, and Edmondson J: Location of the binding site in subcomponent Clq for plasma fibronectin. Acta Pathol Microbiol Immunol Scand 1984;92(Suppl 284):11–17.
24. Bartholomew RM. and Esser AF: Differences in activation of human and guinea pig complement by retroviruses. J Immunol 1978;121:1748–1751.
25. Bartholomew RM, Esser AF, and Muller-Eberhard HJ: Lysis of oncornaviruses by human serum; isolation of the viral complement (C1) receptor and identification as p15E. J Exp Med 1978:147:844–853.
26. Tenner AJ, and Cooper NR: Identification of types of cells in human peripheral blood that bind C1q. J Immunol 1981;126:1174–1179.
27. Daha MR. Miltenburg AMM, Hiemstra PS, Klar-Mohamad N, Van Es LA, and Van Hinsbergh VWM: The complement subcomponent Clq mediates binding of immune complexes and aggregates to endothelial cells in vitro. Eur J Immunol 1988;18:783–787.
28. Erdei A, and Reid KB: The C1q receptor. Molec Immunol 1988;25:1067–1073.